GOTHENBURG, Sweden, Nov. 28,
2022 /PRNewswire/ -- Isofol Medical AB (publ)
(Nasdaq Stockholm: ISOFOL), announced today that Chief
Executive Officer Dr. Ulf Jungnelius M.D. and Isofol's Board of
Directors have agreed that Ulf will step down as CEO of Isofol on
June 1, 2023. Isofol's Board of
Directors will take a decision regarding a new CEO once the
company's future has been determined.
The information in the press release is intended for
investors.
Dr. Ulf Jungnelius M.D. and Isofol have agreed that Ulf will
leave his position as CEO of Isofol Medical on June 1, 2023. Until then he will be fully focused
in leading Isofol as it completes the closure of the AGENT and to
assess possible future paths forward for the Company.
"As CEO, Ulf brought a valuable know-how and ability to oversee
a large phase III clinical trial in oncology. We would like to
thank Ulf for his hard work and dedication in taking the AGENT
study to conclusive although disappointing results," said Jan
Törnell, Chairman of Isofol Board of Directors.
"Drug development is always a high-risk enterprise, but
competent teams and dedicated shareholders are needed to make
progress in fighting cancer. I would like to thank Isofol's
shareholders, staff and board for their trust and confidence in
allowing me to lead Isofol's effective and decisive completed phase
III study," said Ulf Jungnelius.
For further information, please contact
Jan Törnell, chairman of the board
E-mail: jan.tornell@innoext.se
Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., CEO
E-mail: jungnelius@isofolmedical.com
Telephone: +46 709-16 89 55
This is information that Isofol Medical AB is obliged to make
public pursuant to the EU Market Abuse Regulation. This information
was submitted for publication, through the agency of the contact
person set out above, at 17:55 CET on
November 28, 2022.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical-stage biotechnology
company that is developing and improving the current standard
treatment for patients suffering from cancer by increasing
treatment efficacy through the use of cytostatics. Isofol is
focused on developing a drug for first-line treatment of advanced
colorectal cancer (mCRC) and is trying to improve the current
clinical practice by realizing the full strength of 5-FU with the
addition of arfolitixorin. Isofol has an exclusive global licensing
agreement with Merck & Cie in Schaffhausen, Germany to develop and commercialize
arfolitixorin in oncology. Isofol Medical AB (publ) is traded on
Nasdaq Stockholm.
www.isofolmedical.com
The following files are available for download:
https://mb.cision.com/Main/15598/3674196/1699987.pdf
|
20221128_Isofol_PM_CEO
steps down_final
|
View original
content:https://www.prnewswire.com/news-releases/ceo-ulf-jungnelius-to-leave-isofol-medical-on-june-1-2023-301688063.html
SOURCE Isofol Medical AB (publ)